ArticleJournal of thoracic disease2026
Development and internal validation of a prognostic model for cancer-specific survival in elderly patients with metastatic non-small cell lung cancer: a SEER-based study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognosis of elderly patients with distant metastasis (stage M1) of non-small cell lung cancer (NSCLC) is poor. This study aimed to develop and internally validate a prognostic model for estimating cancer-specific survival (CSS) in elderly patients with metastatic NSCLC. Methods: Clinical data of stage M1 NSCLC patients (2010-2022) were extracted from the Surveillance, Epidemiology, and End Results database and randomly split into a training cohort and an internal validation cohort at a ratio of 7:3. The primary outcome was CSS, defined as death from NSCLC. Prespecified demographic, tumor, metastatic, and treatment-related variables were evaluated using univariate and multivariable Cox proportional hazards regression analyses, followed by bidirectional stepwise selection based on the Akaike information criterion. The cohort was randomly divided into training and internal validation cohorts at a ratio of 7:3. Model discrimination was assessed using the concordance indices (C-indexes) and time-dependent area under the receiver operating characteristic curve (AUC) at 1, 3, and 5 years, while calibration and decision curve analysis were used to evaluate model performance. A nomogram was developed based on the final model. Results: A total of 69,516 patients were randomly allocated in the training (n=48,661) and validation (n=20,855) cohorts. In the training cohort, Cox regression analysis identified independent prognostic factors for CSS (all P Conclusions: This study developed and internally validated a prognostic model and corresponding nomogram for estimating 1-, 3-, and 5-year CSS in elderly patients with stage M1 NSCLC. The model showed moderate and relatively consistent discriminative ability and may assist prognostic risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.